08.40 Evaluation of structural damage evolution in rheumatoid arthritis (ra) with optimisedoptimized doses of biological therapies (bt)

    loading  Checking for direct PDF access through Ovid

Abstract

Background

RA is the most common chronic inflammatory arthropathy. About 30% of patients are treated with BT. The optimisation of BT doses in patients in clinical remission of the disease is a strategy used in clinical practice. The best method for assessing structural damage in daily clinical practice is the SENS method (simplified form of the Van der Heijde method).

Background

The main endpoint was evaluate the evolution of the structural damage of the disease in a cohort of patients with RA in follow-up in Rheumatology Unit, of Valme University Hospital, receiving optimised doses of BT, according to the BT dose optimisation protocol elaborated in our unity.

Materials and methods

Observational, descriptive, longitudinal and retrospective study in a cohort of 32 patients diagnosed with RA (ACR 1987), who are treated at reduced doses of TB.

Materials and methods

A description of the baseline characteristics was made.

Materials and methods

The evolution of structural damage was measured using the SENS method on hand radiographs. The evaluation was done at different moments of the evolution: before the reduction, at the end of the reduction and in the current visit of collection of results.

Result

62.5% are women, mean age at diagnosis of 42.6 years. The duration of RA at the start of BT was 98.63 months and the biological treatment time at the beginning of the optimisation was 160.66 months

Result

The 75% of the sample was FR positive and 56.7% ACPA positive. The 59.4% were with etanercept.

Result

The mean of SENS score in hands before the optimisation was 8.78. The mean of SENS score in patients who continued optimised at time of analysis was 10.67. There were no statistically significant differences.

Conclusions

All the patients in our study were in clinical remission of the disease at the beginning of the dose reduction of TB.

Conclusions

The results of our study suggest that optimised doses of BT in patients in clinical remission maintains the patient without significant progression of structural damage.

Related Topics

    loading  Loading Related Articles